跳至主要内容

Cell Viability Assay

 In vitro biological activity detection is a mandatory item for clinical application of biological products, with high requirements for method development, personnel operation stability, and laboratory compliance management. Medicilon's cell viability assay platform can provide compliant in vitro cell viability detection services that meet the application requirements. Our high-level scientific research team can assist customers in participating in new drug development and exploring drug action mechanisms, while our high-throughput screening platform can help customers conduct efficient drug screening.



Empowering new drug development
  • Wide variety
    Medicilon offers over 400 kinds of cell models, providing detection services and functional assay services for various signal pathways.
  • Various Methods
    Cell viability assaysReporter gene assaysTR-FRETFACSRadioactive assaysmRNA and protein expression level detection

  • Sample provision
    Customers only need to provide compounds of the target point to be tested, and we will arrange corresponding detection services and provide professional analysis reports (specific experimental cycle depends on the experiment content).
Test Content
Test items
Test content
Antibody-Mediated Immune Cell Functional Assay
ADCC, CDC, ADCP and ADC inernalization assay.
Cell Viability Assay
Cell proliferation, growth inhibition, cytotoxicity
Cell-based radiometric assay
Isotope-based binding, uptake and proliferation assays.(H3,P32,S35,I125,C14)
ELISA
Cytokine release, Necroptosis assay
FACS assay
T cell/B cell activation and proliferation assay, T cell killing, Binding/Blocking assay, cell cycle analysis, signaling pathway activation.
GPCR assay
GLP-1R/GCGR/GIPR/GLP-2R, HTRF/Reproter Assay/Calcium Influx
Immunoblot Analysis
Protein Phosphorylation/Degradation
In cell Western
Quantification of intracellular signaling in whole cells, IKZF1/3 degradation
Migration assay
Transwell
Reporter assay
NanoBiT, NanoBRET,luciferase, GFP, β-gal, β-lac
RT-PCR
mRNA expression quantification

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...